404 related articles for article (PubMed ID: 27250825)
1. Anti-fibrotic actions of relaxin.
Samuel CS; Royce SG; Hewitson TD; Denton KM; Cooney TE; Bennett RG
Br J Pharmacol; 2017 May; 174(10):962-976. PubMed ID: 27250825
[TBL] [Abstract][Full Text] [Related]
2. The actions of relaxin on the human cardiovascular system.
Sarwar M; Du XJ; Dschietzig TB; Summers RJ
Br J Pharmacol; 2017 May; 174(10):933-949. PubMed ID: 27239943
[TBL] [Abstract][Full Text] [Related]
3. Relaxin as an anti-fibrotic treatment: Perspectives, challenges and future directions.
Samuel CS; Bennett RG
Biochem Pharmacol; 2022 Mar; 197():114884. PubMed ID: 34968489
[TBL] [Abstract][Full Text] [Related]
4. Serelaxin in clinical development: past, present and future.
Unemori E
Br J Pharmacol; 2017 May; 174(10):921-932. PubMed ID: 28009437
[TBL] [Abstract][Full Text] [Related]
5. Recent progress in the understanding of relaxin family peptides and their receptors.
Summers RJ
Br J Pharmacol; 2017 May; 174(10):915-920. PubMed ID: 28447360
[TBL] [Abstract][Full Text] [Related]
6. Vascular actions of relaxin: nitric oxide and beyond.
Leo CH; Jelinic M; Ng HH; Marshall SA; Novak J; Tare M; Conrad KP; Parry LJ
Br J Pharmacol; 2017 May; 174(10):1002-1014. PubMed ID: 27590257
[TBL] [Abstract][Full Text] [Related]
7. The anti-fibrotic actions of relaxin are mediated through AT
Wang C; Pinar AA; Widdop RE; Hossain MA; Bathgate RAD; Denton KM; Kemp-Harper BK; Samuel CS
FASEB J; 2020 Jun; 34(6):8217-8233. PubMed ID: 32297670
[TBL] [Abstract][Full Text] [Related]
8. Synthetic non-peptide low molecular weight agonists of the relaxin receptor 1.
Agoulnik AI; Agoulnik IU; Hu X; Marugan J
Br J Pharmacol; 2017 May; 174(10):977-989. PubMed ID: 27771940
[TBL] [Abstract][Full Text] [Related]
9. Relaxin and insulin-like peptide 3 in the musculoskeletal system: from bench to bedside.
Ferlin A; De Toni L; Sandri M; Foresta C
Br J Pharmacol; 2017 May; 174(10):1015-1024. PubMed ID: 27059798
[TBL] [Abstract][Full Text] [Related]
10. Antifibrotic Actions of Serelaxin - New Roles for an Old Player.
Samuel CS; Summers RJ; Hewitson TD
Trends Pharmacol Sci; 2016 Jun; 37(6):485-497. PubMed ID: 26996448
[TBL] [Abstract][Full Text] [Related]
11. Relaxin family peptides: structure-activity relationship studies.
Patil NA; Rosengren KJ; Separovic F; Wade JD; Bathgate RAD; Hossain MA
Br J Pharmacol; 2017 May; 174(10):950-961. PubMed ID: 27922185
[TBL] [Abstract][Full Text] [Related]
12. The effects of relaxin on extracellular matrix remodeling in health and fibrotic disease.
Samuel CS; Lekgabe ED; Mookerjee I
Adv Exp Med Biol; 2007; 612():88-103. PubMed ID: 18161483
[TBL] [Abstract][Full Text] [Related]
13. Relaxin as a treatment for musculoskeletal fibrosis: What we know and future directions.
Nourmahnad A; Javad Shariyate M; Khak M; Grinstaff MW; Nazarian A; Rodriguez EK
Biochem Pharmacol; 2024 Jul; 225():116273. PubMed ID: 38729446
[TBL] [Abstract][Full Text] [Related]
14. Cardioprotective actions of relaxin.
Martin B; Romero G; Salama G
Mol Cell Endocrinol; 2019 May; 487():45-53. PubMed ID: 30625345
[TBL] [Abstract][Full Text] [Related]
15. Relaxin and fibrosis: Emerging targets, challenges, and future directions.
Kanai AJ; Konieczko EM; Bennett RG; Samuel CS; Royce SG
Mol Cell Endocrinol; 2019 May; 487():66-74. PubMed ID: 30772373
[TBL] [Abstract][Full Text] [Related]
16. Structural commonality of C1q TNF-related proteins and their potential to activate relaxin/insulin-like family peptide receptor 1 signalling pathways in cancer cells.
Klonisch T; Glogowska A; Thanasupawat T; Burg M; Krcek J; Pitz M; Jaggupilli A; Chelikani P; Wong GW; Hombach-Klonisch S
Br J Pharmacol; 2017 May; 174(10):1025-1033. PubMed ID: 27443788
[TBL] [Abstract][Full Text] [Related]
17. Human Recombinant Relaxin (Serelaxin) as Anti-fibrotic Agent: Pharmacology, Limitations and Actual Perspectives.
Sassoli C; Nistri S; Chellini F; Bani D
Curr Mol Med; 2022; 22(3):196-208. PubMed ID: 33687895
[TBL] [Abstract][Full Text] [Related]
18. Sex-specific effects of relaxin-3 on food intake and body weight gain.
Calvez J; de Ávila C; Timofeeva E
Br J Pharmacol; 2017 May; 174(10):1049-1060. PubMed ID: 27245781
[TBL] [Abstract][Full Text] [Related]
19. Receptor-independent modulation of TGF-β-induced pro-fibrotic pathways by relaxin-2 in human primary tubular epithelial cells.
Grampp S; Goppelt-Struebe M
Cell Tissue Res; 2018 Dec; 374(3):619-627. PubMed ID: 30078103
[TBL] [Abstract][Full Text] [Related]
20. Functional crosstalk between angiotensin receptors (types 1 and 2) and relaxin family peptide receptor 1 (RXFP1): Implications for the therapeutic targeting of fibrosis.
Samuel CS; Li Y; Wang Y; Widdop RE
Br J Pharmacol; 2024 Jul; 181(14):2302-2318. PubMed ID: 36560925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
